Form 4: Amgen EVP David M. Reese Reports Stock Transactions

David M. Reese, EVP & Chief Technology Officer of Amgen, reports the exercise of stock options and subsequent sale of Amgen shares.

Summary

• On February 19, 2025, David M. Reese exercised stock options to acquire 8,711 shares of Amgen common stock at a price of $156.35 per share.
• Also on February 19, 2025, Reese sold 8,711 shares of Amgen common stock at an average price of $293.2182, with prices ranging from $291.90 to $295.97 per share.
• On February 21, 2025, Reese sold an additional 25,225 shares of Amgen common stock at an average price of $304.441, with prices ranging from $297.19 to $305.33 per share.
• Following these transactions, Reese directly owns 36,922 shares of Amgen common stock, which includes 707 Dividend Equivalents (DEs).

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

This Form 4 filing is a routine disclosure of stock transactions by a company executive, which is common in the pharmaceutical industry. It provides transparency into the executive's trading activities and holdings of company stock.

Comparison to Industry Standards

• Executive stock transactions are a common occurrence in publicly traded companies, including Amgen's competitors such as Johnson & Johnson (JNJ), Pfizer (PFE), and Merck (MRK).
• These companies also have executives who regularly exercise stock options and sell shares, as part of their compensation packages and personal financial planning.
• The reporting requirements and transparency are generally consistent across these companies, adhering to SEC regulations.

Stakeholder Impact

• The stock sales by a high-ranking executive could be perceived negatively by some shareholders, potentially leading to minor selling pressure.
• However, such transactions are common and often part of personal financial planning, so the impact is likely to be minimal.

Key Dates

Keywords

Amgen, David M. Reese, stock options, stock sale, Form 4, insider trading, executive compensation, AMGN